glp 1 weight loss drugs list GLP-1 Medications for Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness GLP-1 diabetes and weight-loss drug

Today, Novo Nordisk estimates that just under 20 million people are treated with GLP-1 drugs.4 Given a well-stocked pipeline, a substantial global addressable population (the obese population alone is projected to exceed 1.2 billion by 20305), and in light of the very beneficial clinical profile of these drugs, it is plausible that over 100 million patients worldwide will be treated with GLP-1s in the near future

Furman BL

The primary modifiable risk factors contributing to CVD worldwide included elevated systolic blood pressure, dietary risks, high levels of LDL cholesterol (LDL-C), tobacco consumption, increased fasting plasma glucose, and insufficient physical activity [24,25]

Or these GLP-1 agonist drugs may have a direct anti-cancer effect by impacting the immune microenvironment, the microbiome, and may be anti-inflammatory

Research published in The Lancet examining GLP-1 receptor agonist eligibility across 99 countries found that eligibility varies dramatically based on which BMI thresholds are used